0001171843-17-007020.txt : 20171114 0001171843-17-007020.hdr.sgml : 20171114 20171114170215 ACCESSION NUMBER: 0001171843-17-007020 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171110 FILED AS OF DATE: 20171114 DATE AS OF CHANGE: 20171114 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BOHLIN GAREN G CENTRAL INDEX KEY: 0001254705 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36694 FILM NUMBER: 171202658 MAIL ADDRESS: STREET 1: C/O PRAECIS PHARMACEUTICALS INC STREET 2: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PROTEON THERAPEUTICS INC CENTRAL INDEX KEY: 0001359931 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 WEST STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 781-890-0102 MAIL ADDRESS: STREET 1: 200 WEST STREET CITY: WALTHAM STATE: MA ZIP: 02451 4 1 formfour.xml OWNERSHIP DOCUMENT X0306 4 2017-11-10 0 0001359931 PROTEON THERAPEUTICS INC PRTO 0001254705 BOHLIN GAREN G C/O PROTEON THERAPEUTICS, INC. 200 WEST STREET WALTHAM MA 02451 1 0 0 0 Common Stock 2017-11-10 4 A 0 23800 1.963 A 23800 D Common Stock 2017-11-13 4 A 0 25700 1.918 A 49500 D Common Stock 2017-11-14 4 A 0 3812 1.889 A 53312 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2017. The purchase price of $1.963 is reflective of the weighted average purchase price of all transactions reported on this line. The prices for the transactions reported on this line range from $1.91 to $2.01. The reporting person undertakes to provide Proteon Therapeutics, Inc., any security holder of Proteon Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The purchase price of $1.918 is reflective of the weighted average purchase price of all transactions reported on this line. The prices for the transactions reported on this line range from $1.905 to $1.96. The reporting person undertakes to provide Proteon Therapeutics, Inc., any security holder of Proteon Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The purchase price of $1.889 is reflective of the weighted average purchase price of all transactions reported on this line. The prices for the transactions reported on this line range from $1.71 to $1.911. The reporting person undertakes to provide Proteon Therapeutics, Inc., any security holder of Proteon Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ George A. Eldridge as attorney-in-fact for Garen Bohlin 2017-11-14